Parkway Shanghai Hospital, operated by IHH Healthcare on the Chinese mainland, has officially launched its International Hepatobiliary and Pancreatic Diagnosis and Treatment Center in a strategic move to position itself as Asia’s leading comprehensive care hub for complex abdominal organ diseases.
The newly inaugurated center represents an innovative public-private healthcare collaboration, bringing together international medical expertise from the University of Hong Kong, Japan’s Keio University, Shanghai First People’s Hospital, and the Wu Mengchao Foundation. This partnership leverages IHH Healthcare’s global network to create an integrated treatment platform that combines resources across multiple specialties including gastroenterology, surgical oncology, critical care medicine, interventional ultrasound, and pathology.
Medical experts emphasize that the center will implement a systematic approach to hepatobiliary and pancreatic care, incorporating advanced preventive medicine protocols, precision diagnostics, and minimally invasive treatment technologies. The facility aims to assemble renowned specialists from across the globe to create a diversified international platform that addresses the full spectrum of patient needs from early detection through complex surgical interventions.
As Shanghai’s designated pilot demonstration base for international medical tourism, Parkway Shanghai Hospital will continuously introduce cutting-edge treatment methodologies and global technological innovations through IHH’s extensive healthcare network. The center is positioned to deliver high-quality, specialized care not only to patients within the Yangtze River Delta region but throughout the Asia-Pacific, potentially transforming regional standards for hepatobiliary and pancreatic disease management.